Compositions and methods for treating cancer with anti-ROR1 immunotherapy

US10428141B2 · kind B2 · utility

Assignees

• LENTIGEN TECHNOLOGY, INC. · US
• The U.S.A., as represented by The Secretary, Department of Health and Human Services · US

Inventors

• Rimas J. Orentas · Seattle, US
• Dina Schneider · Potomac, US
• Boro Dropulic · Ellicott City, US
• Dimiter S. Dimitrov · Frederick, US
• Zhongyu Zhu · Frederick, US

Key dates

• Filing date: Nov 2, 2018
• Grant date: Oct 1, 2019
• Expiry date: Nov 2, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16043
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Chimeric antigen receptors containing ROR1 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.